nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.05.2013 | Original article

Radiotherapy for carcinoma of the vagina

Immunocytochemical and cytofluorometric analysis of prognostic factors

verfasst von: P. Blecharz, M. Reinfuss, J. Ryś, J. Jakubowicz, P. Skotnicki, W. Wysocki

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

The aim of this study was to assess the potential prognostic factors in patients with primary invasive vaginal carcinoma (PIVC) treated with radical irradiation.

Patients and methods

The analysis was performed on 77 patients with PIVC treated between 1985 and 2005 in the Maria Skłodowska-Curie Memorial Institute of Oncology, Cancer Center in Krakow. A total of 36 patients (46.8 %) survived 5 years with no evidence of disease (NED). The following groups of factors were assessed for potential prognostic value: population-based (age), clinical (Karnofsky Performance Score [KPS], hemoglobin level, primary location of the vaginal lesion, macroscopic type, length of the involved vaginal wall, FIGO stage), microscopic (microscopic type, grade, mitotic index, presence of atypical mitoses, lymphatic vessels invasion, lymphocytes/plasmocytes infiltration, focal necrosis, VAIN-3), immunohistochemical (protein p53 expression, MIB-1 index), cytofluorometric (ploidity, index DI, S-phase fraction, proliferation index SG2M) factors.

Results

Significantly better 5-year NED was observed in patients: < 60 years, KPS ≥ 80, FIGO stage I and II, grade G1–2, MIB-1 index < 70, S-phase fraction < 10, and proliferation index < 25. Independent factors for better prognosis in the multivariate Cox analysis were age < 60 years, FIGO stage I or II, and MIB-1 index < 70.

Conclusion

Independent prognostic factors in the radically irradiated PIVC patients were as follows: age, FIGO stage, MIB-1 index.

Ali MM, Huang DT, Gopleru DR et al (1996) Radiation alone for carcinoma of the vagina. Variation in response related to the location of the primary tumor. Cancer 77:1934–1939PubMedCrossRef

Alt CD, Brocker KA, Eichbaum M et al (2011) Imaging of female pelvic malignancies regarding MRI, CT and PET/CT. Part 2. Strahlenther Onkol 187:705–714PubMedCrossRef

Beller U, Sideri M, Maisonneuve P et al (2001) Carcinoma of the vagina. J Epidemiol Biostat 6:141–152PubMed

Bouma J, Burger MPM, Krans M et al (1994) Squamous cell carcinoma of the vagina: a report of 32 cases. Int J Gynecol Cancer 4:389–394PubMedCrossRef

Cardenes HR, Perez CA (2008) Vagina. In: Halperin EC, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1657–1681

Cardenes MR, Schilder JM, Roth LM (2009) Vagina. In: Barakat RR, Markman M, Randall ME (eds) Principles and practice of gynecologic oncology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 591–622

Chyle V, Zagars GK, Wheeler JA et al (1996) Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 35:891–905PubMedCrossRef

Cox DR (1972) Regression models and life tables. J R Stat Soc Series B Stat Methodol 34:187–220

Creasman WT, Phillips JL, Menck HR (1998) The national cancer data base report on cancer of the vagina. Cancer 83:1033–1040PubMedCrossRef

10.

Crevoisier R de, Sanfilippo N, Gerbaulet A et al (2007) Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol 85:362–370PubMedCrossRef

11.

Dancuart F, Delclos L, Wharton JT, Silva EG (1988) Primary squamous cell carcinoma of the vagina treated by radiotherapy: a failures analysis—the MD Anderson Hospital experience 1955–1982. Int J Radiat Oncol Biol Phys 14:745–749PubMedCrossRef

12.

Dixit S, Singhal S, Baboo HA (1993) Squamous cell carcinoma of the vagina: a review of 70 cases. Gynecol Oncol 48:80–87PubMedCrossRef

13.

Eifel PJ, Berek JS, Markman MA (2008) Cancer of the cervix, vagina, and vulva. In: De Vita VT, Lawrence TS, Rosenberg SA (eds) DeVita, Hellman, and Rosenberg’s cancer. Principles and practice of oncology, 2nd edn. Lippincott Williams and Wilkins, Philadelphia, pp 1521–1542

14.

Fine BA, Piver MS, McAuley M, Driscoll D (1996) The curative potential of radiation therapy in the treatment of primary vaginal carcinoma. Am J Clin Oncol 19:39–44PubMedCrossRef

15.

Frank SJ, Jhingran A, Levenback C et al (2005) Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 62:138–147PubMedCrossRef

16.

Fraunholz IB, Schopohl B, Böttcher MD (1998) Management of radiation injuries of vulva and vagina. Strahlenther Onkol 174(Suppl 3):90–92PubMed

17.

Gesta P, Fenton J, Mathieu G et al (1989) Cancer du vagin épithélioma épidermoide primitif invasif de l’adulte. Bull Cancer 76:591–604PubMed

18.

Gray HJ (2010) Advances in vulvar and vaginal cancer treatment. Gynecol Oncol 118:3–5 (Editorial)PubMedCrossRef

19.

Hacker NF (2005) Vaginal cancer. In: Berek JS, Hacker NF (eds) Practical gynecologic oncology, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 585–602

20.

Hegemann S, Schäfer U, Lellé R et al (2009) Long-term results of radiotherapy in primary carcinoma of the vagina. Strahlenther Onkol 185:184–189PubMedCrossRef

21.

Hellman K, Lundell M, Silfverswärd C et al (2006) Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer 16:1201–1211PubMedCrossRef

22.

Jhingran A, Russell AH, Seiden MV et al (2008) Cancers of the cervix, vulva, and vagina. In: Abeloff MD, Armitage JO, Niederhuber JE et al (eds) Abeloff’s clinical oncology, 4th edn. Elsevier, Philadelphia, pp 1778–1791

23.

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

24.

Kirkbride P, Fyles A, Rawlings GA et al (1995) Carcinoma of the vagina—experience at the Princess Margaret Hospital (1974–1989). Gynecol Oncol 56:435–443PubMedCrossRef

25.

Kosary CL (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10:31–46PubMedCrossRef

26.

Kucera H, Langer M, Smekal G, Weghaupt K (1984) Zum Einfluss von Brachy—und Teletherapie auf das Behandlungsergebnis beim primären Vaginalkarzinom. Strahlentherapie 160:184–190PubMed

27.

Kucera H, Langer M, Smekal G, Weghaupt K (1985) Radiotherapy of primary carcinoma of the vagina: management and results of different therapy schemes. Gynecol Oncol 21:87–93PubMedCrossRef

28.

Kucera H, Vavra N (1991) Radiation management of primary carcinoma of the vagina: clinical and histopathological variables associated with survival. Gynecol Oncol 40:12–16PubMedCrossRef

29.

Leminen A, Forss M, Lehtovirta P (1995) Therapeutic and prognostic considerations in primary carcinoma of the vagina. Acta Obstet Gynecol Scand 74:379–383PubMedCrossRef

30.

Leung S, Sexton M (1993) Radical radiation therapy for carcinoma of the vagina—impact of treatment modalities on outcome: Peter MacCallum Cancer Institute experience 1970–1990. Int J Radiat Oncol Biol Phys 25:413–418PubMedCrossRef

31.

Lian J, Dundas G, Carlone M et al (2008) Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol 111:298–306PubMedCrossRef

32.

Malmström H, Simonsen E, Tropé C (1989) Primary invasive squamous cell carcinoma of the vagina. Acta Obstet Gynecol Scand 68:411–415PubMedCrossRef

33.

Mock U, Kucera H, Fellner C et al (2003) High-dose-rate (HDR) brachytherapy with or without external beam radiotherapy in the treatment of primary vaginal carcinoma: long-term results and side effects. Int J Radiat Oncol Biol Phys 56:950–957PubMedCrossRef

34.

Nashiro T, Yagi C, Hirakawa M et al (2008) Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. Int J Clin Oncol 13:335–339PubMedCrossRef

35.

Nori D, Hilaris BS, Stanimir G, Lewis JL Jr (1983) Radiation therapy of primary vaginal carcinoma. Int J Radiat Oncol Biol Phys 9(10):1471–1475PubMedCrossRef

36.

Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics, 1997. Ca Cancer J Clin 47:5–27PubMedCrossRef

37.

Perez CA, Grigsby PW, Garipagaoglu M et al (1999) Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys 44:37–45PubMedCrossRef

38.

Peters WA, Kumar NB, Morley GW (1985) Carcinoma of the vagina. Factors influencing treatment outcome. Cancer 55:892–897PubMedCrossRef

39.

Peto R, Pike MC, Armitage P et al (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39PubMedCrossRef

40.

Pingley S, Shrivastava KS, Sarin R et al (2000) Primary carcinoma of the vagina: Tata Memorial Hospital experience. Int J Radiat Oncol Biol Phys 46:101–108PubMedCrossRef

41.

Reddy S, Saxena VS, Reddy S et al (1991) Results of radiotherapeutic management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys 21:1041–1044PubMedCrossRef

42.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140PubMed

43.

Schäfer U, Micke O, Prott FJ et al (1997) Ergebnisse der primären Strahlentherapie beim Vaginalkarzinom. Strahlenther Onkol 173:272–280PubMedCrossRef

44.

Seeger AR, Windschall A, Lotter M et al (2006) The role of interstitial brachytherapy in the treatment of vaginal and vulvar malignancies. Strahlenther Onkol 182:142–148PubMedCrossRef

45.

Shah CA, Goff BA, Lowe K et al (2009) Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol 113:1038–1045PubMed

46.

Shankey TV, Rabinovitch PS, Bagwell B (1993) Guidelines for implementation of clinical DNA cytometry. Cytometry 14:472–477PubMedCrossRef

47.

Sinha B, Stehman F, Schilder J et al (2009) Indiana University experience in the management of vaginal cancer. Int J Gynecol Cancer 19:686–693PubMedCrossRef

48.

Spirtos NM, Doshi BP, Kapp DS, Teng N (1989) Radiation therapy for primary squamous cell carcinoma of the vagina: Stanford University experience. Gynecol Oncol 35:20–26PubMedCrossRef

49.

Stock RG, Mychalczak B, Armstrong JG et al (1992) The importance of brachytherapy technique in the management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys 24:747–753PubMedCrossRef

50.

Stock RG, Chen ASJ, Seski J (1995) A thirty-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 56:45–52PubMedCrossRef

51.

Stryker JA (2000) Radiotherapy for vaginal carcinoma: a 23-year review. Br J Radiol 73:1200–1205PubMed

52.

Tavassoli FA, Devilee P (2003) Pathology and genetics of tumours of the breast and female genital organs. WHO classification of tumours. IARCP Press, Lyon, pp 291–308

53.

Tawari KS, Cappuccini F, Puthawala AA et al (2001) Primary invasive carcinoma of the vagina. Treatment with interstitial brachytherapy. Cancer 91:758–770CrossRef

54.

Tran PhT, Su Z, Lee P et al (2007) Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 105:641–649PubMedCrossRef

55.

Urbański K, Kojs Z, Reinfuss M, Fabisiak W (1996) Primary invasive vaginal carcinoma treated with radiotherapy: analysis of prognostic factors. Gynecol Oncol 60:16–21PubMedCrossRef

56.

Vavra N, Seifert M, Kucera H et al (1991) Die Strahlentherapie des primären vaginal Karzinoms und der Einfluss histologischer und klinisher Faktoren auf die Prognose. Strahlenther Onkol 167:1–6PubMed

57.

Waggoner SE, Anderson SM, Luce MC et al (1996) P53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. Gynecol Oncol 60:339–344PubMedCrossRef

58.

Wu X, Matanoski G, Chen VW et al (2008) Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer 113 (10 Suppl):2873–2882PubMedCrossRef

Titel: Radiotherapy for carcinoma of the vagina
Immunocytochemical and cytofluorometric analysis of prognostic factors
verfasst von: P. Blecharz
M. Reinfuss
J. Ryś
J. Jakubowicz
P. Skotnicki
W. Wysocki
Publikationsdatum: 01.05.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0291-0

Springer Medizin

Radiotherapy for carcinoma of the vagina

Immunocytochemical and cytofluorometric analysis of prognostic factors

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Lebensqualität nach Chirurgie oder Radiochirurgie von Hirnmetastasen und adjuvanter Ganzhirnbestrahlung

Erratum to: Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?

Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer

Frühe postoperative Strahlentherapie nach radikaler Prostatektomie bei „High-risk“-Prostatakarzinompatienten weiterhin Standard

Mitteilungen der Fachgesellschaften

Comparison of four target volume definitions for pancreatic cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie